Effects of indomethacin and leupeptin on muscle cathepsin B activity and protein degradation during sepsis

1988 ◽  
Vol 45 (1) ◽  
pp. 140-144 ◽  
Author(s):  
Robert P. Hummel ◽  
Brad W. Warner ◽  
J.Howard James ◽  
Per-Olof Hasselgren ◽  
Josef E. Fischer
2004 ◽  
Vol 279 (46) ◽  
pp. 48426-48433 ◽  
Author(s):  
Zachary B. Mackey ◽  
Theresa C. O'Brien ◽  
Doron C. Greenbaum ◽  
Rebecca B. Blank ◽  
James H. McKerrow

1977 ◽  
Vol 164 (2) ◽  
pp. 399-407 ◽  
Author(s):  
Melvyn F. Hopgood ◽  
Michael G. Clark ◽  
F. John Ballard

1. Isolated parenchymal cells were prepared by collagenase perfusion of livers from fed rats that had been previously injected with [3H]leucine to label liver proteins. When these cells were incubated in a salts medium containing glucose, gelatin and EDTA, cellular integrity was maintained over a period of 6h. 2. Cells incubated in the presence of 2mm-leucine to minimize radioactive isotope reincorporation released [3H]leucine into the medium at a rate accounting for the degradation of 4.5% of the labelled cell protein per h. 3. Degradation of [3H]protein in these cells was inhibited by insulin and by certain amino acids, of which tryptophan and phenylalanine were the most effective. 4. Protein degradation was decreased by several proteinase inhibitors, particularly those that are known to inhibit lysosomal cathepsin B, and by inhibitors of cell-energy production. 5. Ammonia inhibited degradation, but only at concentrations above 1.8mm. Aliphatic analogues of ammonia were effective at lower concentrations than was ammonia. 6. High concentrations of ammonia inhibited degradation by 50%. The extent of this inhibition could not be increased further by the addition of the cathepsin B inhibitor leupeptin, which by itself inhibited degradation by approx. 30%. 7. The sensitivity of proteolysis in isolated hepatocytes to these various inhibitory agents is discussed in relation to their possible modes of action.


2020 ◽  
Author(s):  
Celestina Mazzotta ◽  
Grace Marden ◽  
Alessandra Farina ◽  
Andreea Bujor ◽  
Marcin A. Trojanowski ◽  
...  

2007 ◽  
Vol 45 (08) ◽  
Author(s):  
F Weiss ◽  
CO Behn ◽  
P Simon ◽  
W Halangk ◽  
MM Lerch
Keyword(s):  

Author(s):  
Cyrille Kounde ◽  
Maria M. Shchepinova ◽  
Edward Tate

A caging group has been appended to a widely used Von Hippel Lindau (VHL) E3 ligase ligand for targeted protein degradation with PROTACs. Proteolysis is triggered only after a short irradiation time allowing spatiotemporal control of the protein’s fate.


Author(s):  
Martin Reynders ◽  
Bryan Matsuura ◽  
Marleen Bérouti ◽  
Daniele Simoneschi ◽  
Antonio Marzio ◽  
...  

<p><i>PROTACs (proteolysis targeting chimeras) are bifunctional molecules that tag proteins for ubiquitylation by an E3 ligase complex and subsequent degradation by the proteasome. They have emerged as powerful tools to control the levels of specific cellular proteins and are on the verge of being clinically used. We now introduce photoswitchable PROTACs that can be activated with the temporal and spatial precision that light provides. These trifunctional molecules, which we named PHOTACs, consist of a ligand for an E3 ligase, a photoswitch, and a ligand for a protein of interest. We demonstrate this concept by using PHOTACs that target either BET family proteins (BRD2,3,4) or FKBP12. Our lead compounds display little or no activity in the dark but can be reversibly activated to varying degrees with different wavelengths of light. Our modular and generalizable approach provides a method for the optical control of protein levels with photopharmacology and could lead to new types of precision therapeutics that avoid undesired systemic toxicity.</i><b></b></p>


Sign in / Sign up

Export Citation Format

Share Document